| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.35 |
4e-18 |
| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.4 |
9e-15 |
| mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.33 |
1e-14 |
| mRNA |
GDC-0879 |
CTRPv2 |
pan-cancer |
AAC |
0.28 |
1e-11 |
| mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
4e-06 |
| mRNA |
parbendazole |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
8e-06 |
| mRNA |
KX2-391 |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
1e-05 |
| mRNA |
GSK1120212 |
CTRPv2 |
pan-cancer |
AAC |
0.23 |
2e-05 |
| mRNA |
triazolothiadiazine |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
5e-05 |
| mRNA |
paclitaxel |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
6e-05 |